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(OR 1.64; 95% CI 1.01–2.65; p = 0.051) and the insertion allele 
of DHFR c.594 + 59del19bp (OR 1.61; 95% CI 1.00–2.60; p = 
0.059), which were found to be overrepresented in patients. 
 Conclusion: Polymorphisms of homocysteine metabolism 
are possible risk factors for the formation of intracranial an-
eurysms.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Aneurysmal subarachnoid hemorrhage caused by 
ruptured intracranial aneurysms has a 30-day mortality 
rate of up to 45%, and 30% of survivors have moderate-
to-severe disability  [1] . Little is known about the etiology 
of intracranial aneurysms. Hereditary factors are sup-
posed to be involved in the etiology of cerebral aneu-
rysms. In addition to defined diseases like autosomal 
dominant polycystic kidney disease, multiple genetic 
susceptibilities are considered to act together in the etiol-
ogy of subarachnoid hemorrhage  [2] . The increase in the 
familial risk of subarachnoid hemorrhage is approxi-
mately fourfold among first-degree relatives  [3, 4] . Poly-
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 Abstract 
 Background: Impaired homocysteine metabolism is associ-
ated with a number of vasculopathies including extracranial 
aneurysms. We analyzed the possible association of nine 
 genetic variants of homocysteine metabolism with the oc-
currence of intracranial aneurysms.  Methods: Caucasian 
 patients (n = 255) treated at two German hospitals for 
 in tracranial aneurysms and local controls (n = 348) were 
 genotyped for the following polymorphisms: methionine 
synthase (MTR) c.2756A ] G, methylenetetrahydrofolate re-
ductase (MTHFR) c.677C ] T, MTHFR c.1298A ] C, cystathio-
nine   -synthase (CBS) c.844_855ins68, CBS c.833T ] C, dihy-
drofolate reductase (DHFR) c.594 + 59del19bp, glutathione 
S-transferase   -1 (GSTO1) c.428C ] A, reduced folate carrier
1 (RFC1) c.80G ] A and transcobalamin 2 (Tc2) c.776C ] G. 
 Results: The G-allele of the missense polymorphism Tc2 
c.777C ] G was found to be underrepresented in patients, 
suggesting that this variant may protect from the formation 
of cerebral aneurysms [odds ratio per two risk alleles (OR) 
0.48; 95% confidence interval (CI) 0.30–0.77; p = 0.002]. We 
obtained borderline results for the G-allele of RFC1 c.80G ] A 
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morphisms of genes coding for constituents of vascular 
walls or involved in angiogenesis and vascular remodel-
ing have been suggested to be associated with the forma-
tion of cerebral aneurysms  [2] . Polymorphisms affecting 
homocysteine metabolism have been reported to pro-
mote atherosclerosis, ischemic stroke, cervical arterial 
dissections and abdominal aortic aneurysms  [5–7] . In ad-
dition, autosomal recessive deficiency in cystathionine-
  -synthase (CBS; OMIM 236200), which is involved in 
homocysteine metabolism, presents concomitant with 
vascular disease including the formation of aneurysms 
 [8] . The present study aimed to analyze whether poly-
morphisms affecting homocysteine metabolism are as-
sociated with the incidence of intracranial aneurysms. 
 Patients and Methods 
 Subjects 
 Patients of Caucasian origin undergoing microsurgery or en-
dovascular treatment for cerebral aneurysms were recruited from 
the Departments of Neurosurgery at the University of Bonn and 
the Technical University of Dresden, Germany. Diagnoses were 
made by brain imaging, including digital subtraction angiogra-
phy in all cases. Patients with known autosomal dominant poly-
cystic kidney disease, fibromuscular dysplasia or with additional 
cerebrovascular dysplasia were excluded  [9] .
 This study was approved by the local ethics committees. Writ-
ten informed consent was obtained from patients or their legal 
representatives.
 As controls we studied 250 apparently healthy Caucasian res-
idents in the area of Bonn (64% female; mean age 50.4  8 11.9 
years) without a history of cerebrovascular disease and 98 Cauca-
sian healthy anonymous blood donors from the Dresden area. 
The Bonn area residents were recruited from an ongoing study on 
cerebrovascular disease. They are healthy partners from patients 
with vascular events, free from any history or ultrasonic signs of 
vascular disease  [10] .
 Genotyping 
 Genomic DNA prepared from peripheral leukocytes was used 
for genotyping by PCR amplification and restriction analysis
of nine genetic variants of homocysteine metabolism including 
the intronic deletion dihydrofolate reductase (DHFR) c.594 + 
59del19bp (affecting the transcript level; GenBank NM_000791.3), 
the splice alteration cystathionine -synthase c.844_855ins68 
(affecting the transcript level; GenBank S78267.1) and the mis-
sense mutations (i.e. leading to amino acid exchanges) methio-
nine synthase (MTR) c.2756A ] G (p.D919G; rs1805087), methy-
lenetetrahydrofolate reductase (MTHFR) c.677C ] T (p.A222V; 
rs1801133) and c.1298A ] C(p.E429A; rs1801131), CBS c.833T ] C 
(p.I278T; rs5742905), glutathione S-transferase   -1 (GSTO1) 
c.428C ] A (p.A140D; rs4925), reduced folate carrier 1 (RFC1) 
c.80G ] A (p.R27H; rs1051266) and transcobalamin 2 (Tc2) 
c.776C ] G (p.P259R; rs1801198)  [11] .
 Statistical Analysis 
 Deviation from and compatibility with the Hardy-Weinberg 
equilibrium was analyzed using a Monte Carlo   2 goodness-of-fit 
test (C - program available from www.imbs-luebeck.de)  [12] and 
the exact uniformly most powerful equivalence test with   2 = 2 
and   1 = 2/3, respectively (SAS macro using SAS version 9.1) [13] . 
As primary analysis, exact logistic regressions between genotypes 
and aneurysms were carried out using the Cochran-Armitage 
trend test for genotypes and stratification by center. Covariates 
were available for the samples from Bonn, and adjustments for
age and gender were performed using the exact logistic regres-
sion framework with trend test coding for genotypes (software 
StatXact 6). Population stratification can be assumed to be negli-
gible in the present study because we extensively investigated pop-
ulation stratification in the entire German population previously 
 [14] . The global test level was set to 5%. Adjustments for multiple 
testing were done according to the step-down procedure of Šidak-
Holm  [15] . Asymptotic 95% confidence intervals (CIs) were com-
puted for genotypes without adjustments for multiple testing for 
the joint analysis of both centers. Exact CIs at the nominal 95% 
confidence level were calculated for each center without adjust-
ments for covariates (SAS 9.1).
 Power calculations using the available sample were carried out 
using the two-sided asymptotic Cochrane-Armitage test at the 
global 0.625% test level that already adjusts for the analysis of 
eight successfully genotyped polymorphisms assuming the ob-
served odds ratios (ORs) and genotype frequencies in the controls 
(StatXact 6).
 Results 
 We investigated 111 patients (74% female, mean age 
51.1  8 12.0 years) of Caucasian origin undergoing mi-
crosurgery or endovascular treatment for cerebral aneu-
rysms at the Department of Neurosurgery, University of 
Bonn, and 144 Caucasian patients admitted to the De-
partment of Neurosurgery, Technical University of Dres-
den (63% female, mean age 51.1  8 12.0 years). Seven fur-
ther patients had been excluded due to autosomal domi-
nant polycystic kidney disease (n = 3), fibromuscular 
dysplasia (n = 1) or other cerebrovascular dysplasia (n = 
3). In 36% of the cases, more than one intracranial aneu-
rysm was diagnosed. 
 The GSTO1 c.428C ] A variant showed deviation from 
the Hardy-Weinberg equilibrium in the controls of Bonn 
(p = 0.02) and was therefore omitted from further analy-
sis. No other deviations were observed in the control pop-
ulations. 
 The genotype distribution of Tc2 c.777C ] G was sig-
nificantly different between patients and controls (p = 
0.002;  table 1 ). We observed borderline significant
results for DHFR c.594 + 59del19bp (p = 0.059) and for 
RFC1 c.80G ] A (p = 0.051). Analysis of the other poly-
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morphisms did not reveal any significant associat -
ions.
 Although population stratification can be assumed to 
be negligible in the present study  [14] , we performed ex-
plorative separate analyses for the Bonn and the Dresden 
populations and found significant differences for the Tc2 
variant in the larger Dresden subgroup (patients, CC: 
0.43, CG: 0.41, GG: 0.16; controls, CC: 0.23, CG: 0.51, GG: 
0.26; p = 0.003), but not for the smaller Bonn subgroup, 
although the GG genotype was underrepresented in both 
patient populations (patients, CC: 0.33, CG: 0.50, GG: 
0.17; controls, CC: 0.30, CG: 0.44, GG: 0.26; p = 0.161). 
Similarly, the distribution of the DHFR genotypes was 
significantly different between patients and controls in 
the Dresden population (patients, del/del: 0.14, del/ins: 
0.46, ins/ins: 0.41; controls, del/del: 0.27, del/ins: 0.44, ins/
ins: 0.29; p = 0.010) but not in the Bonn population (pa-
tients, del/del: 0.15, del/ins: 0.55, ins/ins: 0.30; controls, 
del/del: 0.21, del/ins: 0.45, ins/ins: 0.34; p = 0.809). Con-
cerning the RFC1 polymorphism, the distribution of ge-
notypes was significantly different between patients and 
controls in the Bonn population (patients, AA: 0.24, AG: 
Table 1. Polymorphisms of homocysteine metabolism and aneurysm formation in Caucasian patients from 
Bonn (n = 111) and Dresden (n = 144)
Genotype Patients Controls p value
n % n % OR 95% CI
CBS c.833T]C: p = 1.00
TT 250 98.8 341 98.6 1.00
CT 3 1.2 5 1.4 0.98 0.22–4.34
CC 0 0.0 0 0.0 0.96 0.05–18.8
CBS c.844ins68: p = 0.440
del/del 216 86.7 306 88.4 1.00
ins/del 32 12.9 40 11.6 1.26 0.76–2.08
ins/ins 1 0.4 0 0.0 1.58 0.58–4.33
MTHFR c.677C]T: p = 0.984
CC 116 46.0 158 45.7 1.00
CT 109 43.3 152 43.9 0.99 0.77–1.28
TT 27 10.7 36 10.4 0.98 0.59–1.63
MTHFR c.1298A]C: p = 0.609
AA 117 46.4 161 46.4 1.00
AC 113 44.8 150 43.2 0.93 0.71–1.20
CC 22 8.7 36 10.4 0.86 0.51–1.44
MTR c.2756A]G: p = 0.675
AA 168 66.4 223 64.3 1.00
AG 81 32.0 112 32.3 0.92 0.67–1.27
GG 4 1.6 12 3.5 0.85 0.45–1.61
DHFR c.594 + 59del19bp: p = 0.059
del/del 35 14.1 78 22.7 1.00
del/ins 124 49.8 153 44.5 1.27 1.00–1.61
ins/ins 90 36.1 113 32.8 1.61 1.00–2.60
RFC1 c.80G]A: p = 0.051
AA 76 31.1 129 38.1 1.00
AG 118 48.4 154 45.4 1.28 1.01–1.63
GG 50 20.5 56 16.5 1.64 1.01–2.65
Tc2 c.776C]G: p = 0.002
CC 97 38.5 96 28.1 1.00
CG 113 44.8 157 45.9 0.69 0.55–0.88
GG 42 16.7 89 26.0 0.48 0.30–0.77
Numbers of genotypes (n) observed and ratios (%) per polymorphism are depicted. Nominal two-sided p 
values from an exact logistic regression with center as covariate are shown using the trend test coding for ge-
notypes. Asymptotic CIs were calculated for the joint analysis of both centers.
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0.53, GG: 0.23; controls, AA: 0.38, AG: 0.46, GG: 0.16; p = 
0.012) but not in the Dresden population (patients, AA: 
0.37, AG: 0.44, GG: 0.19; controls, AA: 0.37, AG: 0.45, GG: 
0.18; p = 0.926). 
 The power to detect effects of DHFR and RFC1 was 
only 51 and 52%, respectively, after adjustments for mul-
tiple testing. In contrast, the power to detect the effect of 
Tc2 c.777C ] G was 81% even after adjustments for mul-
tiple testing. 
 None of the polymorphisms investigated was signif-
icantly associated with the multiplicity of aneurysms, 
and no significant association with single or multiple an-
eurysms was seen in subgroups defined by age (not 
shown). 
 Discussion 
 We analyzed nine functional polymorphisms of me-
thionine metabolism in a total of 255 German patients of 
Caucasian origin treated for intracranial aneurysms 
compared with 348 German controls of Caucasian ori-
gin. The distribution of genotypes of Tc2 c.776C ] G was 
significantly different between patients and controls. Ad-
ditionally, we obtained borderline results for the poly-
morphisms RFC1 c.80G ] A and DHFR c.594 + 59del19bp. 
Subgroup analysis of the Bonn and the Dresden popula-
tion only proved a significant effect in one of these popu-
lations for each of those three polymorphisms. Although 
the allele and genotype frequencies did not significantly 
differ between the two control groups (not shown), we 
cannot exclude that differences in the selection of con-
trols (healthy partners of patients with vascular disease 
vs. anonymous blood donors) might have contributed to 
the different results between the Bonn and the Dresden 
subgroups. Further, within the limits of any association 
study, we cannot exclude random errors associated with 
the small numbers in spite of correction for multiple test-
ing. The results observed in our study require confirma-
tion in a further patient cohort. 
 Previous studies suggested that the G-allele of the Tc2 
c.777C ] G polymorphism, which was underrepresented 
in patients with intracranial aneurysms in our study, af-
fects vitamin B 12 binding affinity and the ability to trans-
port vitamin B 12 into tissues  [16–18] , leading to a reduced 
remethylation of homocysteine to methionine by vitamin 
B 12 -dependent MTR. An impaired homocysteine metab-
olism may lead to an accumulation of asymmetric di-
methylarginine  [19, 20] , which is a major endogenous in-
hibitor of nitric oxide and is strongly predictive of prema-
ture cardiovascular disease and death  [21,  22] . It has 
already been shown that nitric oxide availability is a key 
requirement for the development of intracranial aneu-
rysms, and intracranial aneurysm formation was pre-
vented by inhibition of nitric oxide synthase (NOS) in a 
rodent model  [23] . The size of intracranial aneurysms is 
significantly smaller in iNOS–/– mice than in iNOS+/+ 
mice  [24] . eNOS polymorphisms have been investigated 
for associations with intracranial aneurysm formation 
and rupture  [25] . We therefore speculate that the protec-
tive effect of the Tc2 c.776G allele found in the present 
study might in part be explained by decreased transport 
capacity of vitamin B 12 in the blood, leading to increased 
levels of asymmetric dimethylarginine and thereby more 
effective NOS inhibition. Also, lower homocysteine re-
methylation by MTR may lead to a higher homocysteine 
turnover via CBS and, therefore, to a lower capacity of 
CBS concerning the second reaction catalyzed by this en-
zyme, the synthesis of the potent vasodilatator H 2 S, which 
may contribute to vascular damage  [26] . 
 The biochemical consequences of the variant DHFR 
c.594 + 59del19bp and the RFC1 c.80G ] A polymor-
phism are less well defined. DHFR converts dihydrofo-
late into 5,10-methylenetetrahydrofolate, a methyl group 
shuttle required for the de novo synthesis of nucleic acids 
as well as the formation of 5-methyltetrahydrofolate by 
MTHFR. The 19-bp deletion in intron-1 of DHFR has 
been associated with the risk of spina bifida  [27–29] . It 
supposedly decreases DHFR gene expression  [29] , and re-
duced DHFR expression might plausibly lead to reduced 
availability of folates for remethylation of homocysteine 
to methionine. Thus, the DHFR variant might specula-
tively have similar biochemical effects as the Tc2 variant. 
The extracellular reduced folate carrier RFC1 takes up 
reduced folates into the cell  [30] . The c.80G ] A polymor-
phism has been suggested to affect folate and homocys-
teine metabolism  [31] . The biochemical consequences for 
intracellular, in particular endothelial, metabolism re-
main speculative. 
 In summary, the data of our study suggest that the 
missense polymorphism Tc2 c.776C ] G may be associ-
ated with the formation of intracranial aneurysms. In ad-
dition, the polymorphisms RFC1 c.80G ] A and DHFR 
c.594 + 59del19bp might also be involved. If these results 
are confirmed in an independent patient cohort, the bio-
chemical effects of these polymorphisms on the intracra-
nial vasculature should be explored in detail. This may 
well yield important new insights into the pathogenesis 
of intracranial aneurysms. 
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